Viking Therapeutics (VKTX) Misses Q3 EPS by 1c

Viking Therapeutics (NASDAQ: VKTX) reported Q3 EPS of ($0.23), $0.01 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.

You May Also Be Interested In

• AI and memory not a classic bubble, but future returns uncertain - strategist
• BlackBerry shares gain premarket as Q2 results, guidance beat estimates
• Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes